Literature DB >> 19936772

Mid-dermal elastolysis revisited.

Thilo Gambichler1.   

Abstract

The clinical as well as histological data of 79 mid-dermal elastolysis (MDE) patients reported in the literature were evaluated. MDE is an acquired skin condition of the elastic tissue predominantly manifesting on the trunk and proximal extremities of young women. Most commonly observed skin changes include patches of well-circumscribed fine wrinkles (type I) and perifollicular papular protrusions (type II). Rarely, MDE may also occur with persistent reticular erythema and wrinkling (type III). The critical diagnostic histopathological feature of MDE is the selective loss of elastic fibres in the mid-dermis. Mild lymphohistiocytic infiltrates, elastophagocytosis of elastic fibres by macrophages, and even multinucleate giant cells are occasionally observed in MDE lesions. Immunohistological studies and cell culture experiments indicate that dysbalances in elastin turnover are associated with pathological degradative processes including increased elastolytic activity that finally lead to loss of elastic fibres in the mid-dermis. First-line differential diagnoses may include closely related conditions such as anetoderma, annular elastolytic giant cell granuloma, cutis laxa acquisita and pseudoxanthoma elasticum-like papillary dermal elastolysis. Future therapeutic approaches in MDE patients should focus on agents that are able to block increased elastase activity and induce elastin synthesis.

Entities:  

Mesh:

Year:  2010        PMID: 19936772     DOI: 10.1007/s00403-009-1004-0

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  12 in total

Review 1.  Generalized Anetoderma after Intravenous Penicillin Therapy for Secondary Syphilis in an HIV Patient.

Authors:  Jason Emer; Daniel Roberts; Harleen Sidhu; Robert Phelps; Herbert Goodheart
Journal:  J Clin Aesthet Dermatol       Date:  2013-08

2.  Linear Lumbar Localized Lysis of Elastic Fibers: A Distinctive Clinical Presentation of Mid-dermal Elastolysis.

Authors:  Philip R Cohen; Jaime A Tschen
Journal:  J Clin Aesthet Dermatol       Date:  2013-07

3.  Acquired Wrinkled Plaques: A Quiz.

Authors:  Caroline de Lorenzi; Sandra Leoni-Parvex; Carlo Mainetti
Journal:  Acta Derm Venereol       Date:  2020-06-18       Impact factor: 3.875

4.  Primary anetoderma in a young male involving palms, soles and the scalp: rarest of the rare.

Authors:  Noopur Jain; Bagirath Singh Rathore; Abhishek Bhardwaj; Rani Bansal
Journal:  Indian J Dermatol       Date:  2015 Mar-Apr       Impact factor: 1.494

5.  Generalized mid dermal elastolysis.

Authors:  Maria João Cruz; Ana Margarida Barros; Filomena Azevedo
Journal:  Dermatol Reports       Date:  2011-12-01

6.  Middermal Elastolysis: Dermal Fibroblasts Cooperate with Inflammatory Cells to the Elastolytic Disorder.

Authors:  Giovanna De Cunto; Arianna Lamberti; Maria Margherita de Santi; Clelia Miracco; Michele Fimiani; Giuseppe Lungarella; Eleonora Cavarra
Journal:  Mediators Inflamm       Date:  2017-09-17       Impact factor: 4.711

Review 7.  Mid-dermal elastolysis: A female-centric disease; case report and updated review of the literature.

Authors:  Jori Hardin; Elaine Dupuis; Richard M Haber
Journal:  Int J Womens Dermatol       Date:  2015-07-26

Review 8.  Pseudoxanthoma elasticum.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2017-05-10       Impact factor: 4.123

9.  A Clinicoimmunohistopathologic Study of Anetoderma: Is Protruding Type More Advanced in Stage Than Indented Type?

Authors:  Jung Eun Kim; Ki Min Sohn; Young Jun Woo; Kwan Ho Jeong; Miri Kim; Jeong Deuk Lee; Jun Young Lee; Hyun Jeong Park; Gyong Moon Kim; Chul Jong Park; Dong Soo Yu; Hoon Kang
Journal:  J Immunol Res       Date:  2016-12-28       Impact factor: 4.818

10.  Local Panatrophy Associated with Pain: A Rare Variant of Local Panatrophy or a New Entity?

Authors:  Di-Qing Luo; Chang-Zheng Huang; Wei Shi; Zhuo Wang; Ding-Yang He
Journal:  Chin Med J (Engl)       Date:  2017-10-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.